PMID- 34405478
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220117
IS  - 1365-3148 (Electronic)
IS  - 0958-7578 (Linking)
VI  - 31
IP  - 6
DP  - 2021 Dec
TI  - Alloimmunisation rate of patients on Daratumumab: A retrospective cohort study of 
      patients in England.
PG  - 474-480
LID - 10.1111/tme.12808 [doi]
AB  - OBJECTIVE: Whilst small-scale studies on rates of alloimmunisation of patients on 
      Daratumumab have been undertaken, no large-scale study has been performed to date 
      on this cohort of patients. BACKGROUND: Patients with multiple myeloma (MM) who 
      are relapsed or refractory to standard treatment are treated with the anti-CD38 
      therapeutic monoclonal antibody, Daratumumab. Due to the complexity of 
      pre-transfusion compatibility testing, many MM patients in England are referred 
      to Red Cell Immunohaematology (RCI) laboratories for investigation and provision 
      of Red Blood Cell (RBC) components. METHODS: Over a 4-month period, patients due 
      to commence, or currently on anti-CD38 therapy were identified and flagged on the 
      RCI Laboratory Information Management System (LIMS). Data was identified and 
      extracted for further analysis. Interrogation of data was performed independently 
      by two subject matter experts, with discrepancies resolved through further 
      enquiry. RESULTS: Of 734 English MM patients, we report an alloimmunisation rate 
      of 0.4% whilst on an anti-CD38 TMAb. This is in line with other smaller cohort 
      studies. CONCLUSION: Given the low rate of RBC alloimmunisation, consideration 
      should be given to revising the pre-transfusion testing regimen in this cohort. 
      This may improve testing costs, turn-around times and evidence-based patient 
      care.
CI  - (c) 2021 British Blood Transfusion Society.
FAU - Bullock, Tom
AU  - Bullock T
AUID- ORCID: 0000-0001-5486-0389
AD  - Red Cell Immunohaematology, NHSBT, Filton Centre, Bristol, UK.
FAU - Foster, Amie
AU  - Foster A
AD  - Red Cell Immunohaematology, NHSBT, Newcastle Centre, Newcastle, UK.
FAU - Clinkard, Bryony
AU  - Clinkard B
AD  - Clinical Audit, NHSBT, Filton Centre, Bristol, UK.
LA  - eng
PT  - Journal Article
DEP - 20210817
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (Antibodies, Monoclonal)
RN  - 4Z63YK6E0E (daratumumab)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1
MH  - *Antibodies, Monoclonal
MH  - Humans
MH  - *Multiple Myeloma/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - CD38
OT  - alloimmunisation
OT  - compatibility testing
OT  - daratumumab
OT  - immunohaematology
OT  - multiple myeloma
OT  - therapeutic monoclonal antibody
OT  - transfusion
EDAT- 2021/08/19 06:00
MHDA- 2022/01/18 06:00
CRDT- 2021/08/18 06:47
PHST- 2021/04/22 00:00 [received]
PHST- 2021/08/07 00:00 [accepted]
PHST- 2021/08/19 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/08/18 06:47 [entrez]
AID - 10.1111/tme.12808 [doi]
PST - ppublish
SO  - Transfus Med. 2021 Dec;31(6):474-480. doi: 10.1111/tme.12808. Epub 2021 Aug 17.